Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine.
SynergiQC, the Quebec-based funding programme created by CQDM, has awarded the funding.
Go deeper with GlobalData
The project is a partnership with Inspirevax and the National Research Council of Canada (NRC).
In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.
The companies have also formed a joint development committee to oversee the vaccine development efforts together.
Oragenics expects that the funding from CQDM will help in developing two to four well-characterised stable CHO pools that express new, cross-protective vaccine antigens with well-established preclinical efficacy using intranasal immunisation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUsing the advanced manufacturing platform of NRC, these vaccine antigens are expected to be quickly deployable in next-generation vaccine formulations.
NRC’s platform was developed for the reference strain SARS-CoV-2 spike antigen.
Oragenics president and CEO Kim Murphy said: “By collaborating with our longstanding partners, we are better able to address the evolving SARS-CoV-2 virus by working to develop broadly protective antigens designed to protect against current and future variants.
“Our pan-coronavirus vaccine candidate presents a potential universal solution to the evolving nature of SARS-CoV-2 and potentially future coronaviruses by targeting mucosal immunity at the source, being readily deployable through faster manufacturing and exhibiting lower barriers for storage and transportation.”
